Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland

11. Literatur 215
204. Jackman RJ, Burbank F, Parker SH, et al. Atypical ductal hyperplasia diagnosed of
stereotactic breast biopsy: Improved reliability with 14-gauge directional, vacuumassisted
biopsy. Radiology 1997;204:485–8.
205. Jackman RJ, Marzini FAjr, Nowels KW. Percutaneous removal of benign mammographic
lesions: comparison of automated large-core and directional vacuum-assisted
stereotactic biopsy techniques. AJR 1998;171:1325–30.
206. Jackson VP. The role of US in breast imaging. Radiology 1990;177:305.
207. Jadad AR, Haynes RB, Hunt D, Browman DP. The Internet and evidence-based
decision-making: a needed synergy for efficient knowledge management in health care.
Can Med Assoc J 2000;162:362–5.
208. Janda M, Obermaier A, Haidinger G, Waldhoer T, Vutuc C. Austrian women’s attitudes
toward and knowledge of breast self-examination. J Cancer Educ 2000;15:91–4.
209. Janes RH, Bouton MS. Initial 300 consecutive stereotactic core-needle breast biopsies
by a Surgical Group. Am J Surg 1994;168:533–7.
210. Jasienska G, Thune I. Lifestyle, hormones and risk of breast cancer. BMJ
2001;322:586–7.
211. Joensuu H, et al. Late mortality from pt1N0M0 breast carcinoma. Cancer 1999;85:
2183–9.
212. Joint Commission on Accrediatation of Healthcare Organizations J. Primer on indicator
development and application. Measuring quality in health care. Illinois:
Oakbrooke Terrace, 1990.
213. Josley S, West M. Racial differences in breast cancer survial. Cancer 2000;88:114–23.
214. Kaiser’s Permanente-Southern California (KPSC). Screening for breast cancer.
Pasadena (CA): Kaiser’s Permanente Southern California, 2001.
215. Kan L, Ollovotto I, Burhenne J. Standardized abnormal interpretation and cancer
detection ratios to assess reading volume and reader performances in a breast screening
program. Radiology 2000;215:563–7.
216. Kaste SC, Hudson MM, Jones DJ, Fryrear R, Greenwald CA, Fleming ID, et al. Breast
masses in women treated for childhood cancer: incidence and screening guidelines.
Cancer 1998;82:784–92.
217. Kaufmann Z, Garstin W, Hayes R, Michell MJ, Baum M. The mammographic
parenchymal patterns of women on hormonal replacement therapy. Clin Radiol 1991;
43:389–92.
218. Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and accuracy of
mammographic screening. Lancet 2000;355:270–4.
219. Kerlikowske K, Barclay J. Outcomes of modern screening mammography. Monogr Natl
Cancer Inst 1997;22:105–11.
220. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density,
and family history on the sensitivity of first screening mammography. JAMA
1996;276:33–43.
221. Kerlikowske K, Salzmann, Phillips KA, Cauley JA, Cummings SR. Continuing
Screening Mammography in Women Aged 70 to 79 Years. Impact on Life Expectancy
and Cost-effectiveness. JAMA 1999;282:2156–63.
222. Kerr D.World summit against cancer for the new millennium.The Charter of Paris.Ann
Oncol 2000;11:253–4.
223. Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: Detection
with screening US – diagnostic yield and tumor characteristics. Radiology 1998;
207:191–9.
224. Koller M, Lorenz W. Quality of life: A deconstruction for clinicians. J R Soc Med
2002;95:481-8.
225. Kopans DB. Review of stereotaxic large-core needle biopsy and surgical biopsy results
in nonpalpable breast lesions. Radiology 1993;189:665–9.